anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of OPDIVO or of other nivolumab products.

Anti-drug antibody and neutralizing antibody responses were monitored throughout the treatment period where the benefit to risk ratio was assessed. Incidence of anti-drug antibodies and neutralizing antibodies are presented in Table 51.

###  Effects of Anti-Drug Antibodies

Presence of treatment-emergent anti-nivolumab antibodies increased nivolumab clearance by up to 20% after administration of nivolumab as monotherapy or in combination with ipilimumab. These anti-drug antibody-associated pharmacokinetic changes were not considered to be clinically significant. There was no identified clinically significant effect of anti-drug antibodies on incidence of infusion-related reactions. The effects of anti-drug antibodies on effectiveness have not been fully characterized.
PROBLEM TO BE SOLVED: To provide a medical treatment service method which enables a patient to confirm the reservation state of medical facilities at arbitrary time and shortens a doctor's consultation time and the wait time for the prescription of medicines. SOLUTION: Reservation determination information on a clinical consultation is displayed on a user terminal 11 through a communication line NW. The patient is able to grasp the reservation state of the clinical consultation and know when the patient can see a doctor. Consequently, the time for which the patient waits in a waiting room is shortened. The doctor recognizes symptoms of the patient on a doctor's terminal 14 through the communication network NW before examining the patient, so items of the examination decreases and prescription is speedily judged. The doctor sends prescription information on medicines from the docotor's terminal 14 to a pharmaceutist's terminal 15 through the communication line NW after examining the patient. The pharmaceutist is able to prepare medicines before the patient visits. Consequently, the wait time of the patient is shortened.
The prepn. of semi-solid prepns. which contain micronised active ingredients comprises (a) warming a mixt. of one or two non-ionic surfactants with an HLB value of 9-18 with 2.3-100 times its wt. of one or more fatty acid esters of formula R1COOR2 (R1 and R2 are each 12-32C alkyl or alkenyl) until it melts; (b) stirring the melt into 10-200 times its wt. of a semi-solid prepn. which has been melted to approx. the same temp.; (c) letting the mixt. cool while it is being stirred; and (d) adding the micronised active ingredient(s) and opt. perfumes.
PURPOSE:To obtain a skin cosmetic having excellent effect to prevent the aging of the skin, by compounding epithelium growth factor together with a compound selected from gamma-aminobutyric acid, vitamin E orotinic acid ester and diisopropylamine dichloroacetate to a base. CONSTITUTION:The titled cosmetic contains (A) 0.0001-0.1wt% epithelium growth factor (EGF) and (B) 0.01-1wt% compound selected from gamma-aminobutyric acid, vitamin E orotinic acid ester and diisopropylamine dichloroacetate. The cosmetic has excellent effect to prevent the aging of the skin, e.g. the effect to improve chapped skin, the effect to improve keratinized skin, the skin- beautifying effect, the effect to accelerate the turn-over speed, etc. The cosmetic exhibits the effect within an extremely short time, i.e. within 1-2 months after starting the application, and keeps the effect for a long period. EGF is a compound existing in various organs and body fluids (submandibular gland, urine, etc.) of human, mouse, horse, etc.
Rationale: Quantitative interstitial abnormalities (QIAs) are a computed tomography (CT) measure of early parenchymal lung disease associated with worse clinical outcomes, including exercise capacity and symptoms. The presence of pulmonary vasculopathy in QIAs and its role in the QIA-outcome relationship is unknown. Objectives: To quantify radiographic pulmonary vasculopathy in QIAs and determine whether this vasculopathy mediates the QIA-outcome relationship. Methods: Ever-smokers with QIAs, outcomes, and pulmonary vascular mediator data were identified from the Genetic Epidemiology of COPD (COPDGene) study cohort. CT-based vascular mediators were right ventricle-to-left ventricle ratio, pulmonary artery-to-aorta ratio, and preacinar intraparenchymal arterial dilation (pulmonary artery volume, 5-20 mm2 in cross-sectional area, normalized to total arterial volume). Outcomes were 6-minute walk distance and a modified Medical Council Research Council Dyspnea Scale score of 2 or higher. Adjusted causal mediation analyses were used to determine whether the pulmonary vasculature mediated the QIA effect on outcomes. Associations of preacinar arterial dilation with select plasma biomarkers of pulmonary vascular dysfunction were examined. Measurements and Main Results: Among 8,200 participants, QIA burden correlated positively with vascular damage measures, including preacinar arterial dilation. Preacinar arterial dilation mediated 79.6% of the detrimental impact of QIA on 6-minute walk distance (56.2-100%; P < 0.001). Pulmonary artery-to-aorta ratio was a weak mediator, and right ventricle-to-left ventricle ratio was a suppressor. Similar results were observed in the relationship between QIA and modified Medical Council Research Council dyspnea score. Preacinar arterial dilation correlated with increased pulmonary vascular dysfunction biomarker levels, including angiopoietin-2 and N-terminal brain natriuretic peptide. Conclusions: Parenchymal QIAs deleteriously impact outcomes primarily through pulmonary vasculopathy. Preacinar arterial dilation may be a novel marker of pulmonary vasculopathy in QIAs.
Patients with Barrett's Esophagus will be enrolled. The intervention is cessation of acid-suppressing medications. Biopsies will be taken during endoscopy at Day 0, 7, and 14.
PROBLEM TO BE SOLVED: To provide the use of a molded contact lens in combination with a pharmaceutical composition suitable for delivery to the eye.SOLUTION: The present invention provides the use of a molded contact lens, which is preferably commercially available and is not specifically designed for corneal correction. Factors in this pharmaceutical composition (e.g., hyaluronidase) form the cornea of the eye to correct eye refractive error. The contact lens and the pharmaceutical composition thereof cause change of a curvature radius of a front face of a cornea, for correcting eye refractive error of the eye. One of the advantages of the technique of the present invention is that a patient having individual visual needs will manage this procedure that meets the need for near vision and distance vision of the patient. The present invention also provides a kit. The kit comprises a molded contact lens, a pharmaceutical composition suitable for delivery to the eye, and instructions, which are useful for the system of the invention.SELECTED DRAWING: None
Garlic supplements are the most consumed herbal products in the United States. The most common health claim made for garlic supplements is cholesterol lowering activity. This claim has not been supported by recent clinical trials and meta-analyses. However, data suggest that it is not necessarily the garlic that has been ineffective, but rather the particular garlic preparations being used. To date, the predominant type of garlic preparation used in these clinical trials has been dried garlic powders. A few clinical trials have reported beneficial lipid effects using an aged garlic extract, and only a small number of inconclusive uncontrolled trials have used fresh garlic. A rigorous trial directly comparing different types of garlic preparations for their effects on serum lipids is needed.

Adults with moderately elevated low density lipoprotein cholesterol (LDL-C) will be randomized to one of four groups for 6 months: fresh garlic, dried powdered garlic tablets, aged garlic extract tablets, or placebo control. The fresh garlic will be provided to patients with "study sandwiches"; all other groups will receive the same study sandwiches without the garlic. All patients will take daily study tablets, but the tablet assignment will be double-blind. Patients will pick up study sandwiches twice a week and study tablets once every 2 weeks for 28 weeks. Blood samples will be taken once a month, with additional blood draws at the start and end of the study.
When surgeons perform procedures under this condition they perform the initial theatre briefing prior to starting an operating list. They then perform 5 minutes of a preloaded simulated task on the robotic console. These tasks are designed to emulate fundamental skills required to perform robot-assisted laparoscopic surgery. They will then proceed to perform surgery as they normally do whilst undergoing EMG and EEG motoring, collecting data at the predefined POIs.
An aqueous synthesis methodology for the preparation of silica nanoparticles (SNPs), core-shell SNPs having, for example, a size of 2 to 15 nm and narrow size-dispersion with size control below 1 nm, i.e. at the level of a single atomic layer. Different types of dyes, including near infrared (NIR) emitters, can be covalently encapsulated within and brightness can be enhanced via addition of extra silica shells. The surface may be functionalized with polyethylene glycol (PEG) groups and, optionally, specific surface ligands. This aqueous synthesis methodology also enables synthesis of 2 to 15 nm sized fluorescent core and core- shell aluminosilicate nanoparticles (ASNPs) which may also be surface functionalized. Encapsulation efficiency and brightness of highly negatively charged NIR fluorophores is enhanced relative to the corresponding SNPs without aluminum.
In the clinical trials, 44% of patients with newly-diagnosed low-risk APL treated with TRISENOX in combination with tretinoin experienced elevated aspartate aminotransferase (AST), alkaline phosphatase, and/or serum bilirubin. These abnormalities resolved with temporary discontinuation of TRISENOX and/or tretinoin. 

Long-term liver abnormalities can occur in patients with APL treated with TRISENOX in combination with tretinoin. In a published series, mild liver dysfunction and hepatic steatosis were seen in 15% and 43%, respectively, of patients at a median of 7 years (range 0 to 14 years) after treatment with arsenic trioxide in combination with tretinoin.

During treatment with TRISENOX, monitor hepatic function tests at least twice weekly during induction and at least once weekly during consolidation. Withhold TRISENOX and/or tretinoin if elevations in AST or alkaline phosphatase occur to greater than 5 times the upper limit of normal and/or elevation in serum total bilirubin occurs to greater than 3 times the upper limit of normal and resume at reduced dose upon resolution [see Dosage and Administration (2.3)].
Patients were slowly injected of 0.08 ug/kg of sufentanil. Patients received remimazolam 0.1mg/kg to maintain sufficient sedation (sufficient sedation as judged by MOAA/S ≤ 4 for 3 consecutive measurements) during endoscopy procedure.
Immunosuppressive factor purified from human immunodeficiency virus (HIV) or from cells and cell lines, such as lymphocytes, macrophages, lymphoblastic cell lines of T-lymphocytic origin, macrophage cell lines or hybridoma cell lines infected with HIV suppresssing the mitogen and antigen response of normal lymphocytes stimulated with mitogens or antigens as well as the growth of IL-2 dependent T-cell lines, being a glycoprotein of molecular weight of 65,000 to 70,000 daltons, losing its activity on boiling, and possibly containing a subunit having a molecular weight of 25,000 to 30,000 daltons. A process for the production of the mentioned factor is given. The mentioned factor, at least one part thereof or directly indicated synthetic analogs of this factor may be used for detecting antibodies in HIV infected persons - i.e. persons that may come to suffer from the acquired immunodeficiency syndrome, also known as AIDS - by neutralizing the effect of these antibodies, in immunological methods, for producing poly- or monoclonal antibodies in animals, for purifying antibodies originating from HIV infected persons - and the antibodies resulting from this production and/or purification, for bringing about immunity for the purpose of prophylaxis or treatment (vaccination) in healthy or HIV infected persons. The antibodies so provided may be used for detecting this factor or its indicated part in serum, body fluids and tissues of HIV infected persons or for neutralizing the whole or at least one part of this factor in HIV infected persons for the purpose of treatment. A filter containing AIDS antibodies for use in plasmaphoretic treatment is mentioned.
The aim was to study the effects of Kinesio Tape on hip abductor muscle strength and EMG activity. Pretest-posttest experimental design was used. The study was conducted in the research lab of the University. Thirty-four athletes with a mean age of 22.08 years participated in the study. For the experimental group Kinesio Tape and for the control group Micropore Tape (MT) was applied over Gluteus Medius (GM) muscle. GM muscle's strength and EMG activity were noted in supine and during the Single-Leg Squat Test (SLST) respectively before and after the intervention. Hip abductor muscle strength measured through a maximum voluntary isometric contraction (MVIC) and GM activation measured through EMG. Handheld dynamometer (Lafayette manual muscle test system), Power Lab EMG system.
BACKGROUND: Hepatitis B virus (HBV) is an enveloped DNA virus that causes chronic hepatitis B (CHB) infection. Annexin, a Ca2+-activated protein, is widely expressed in various organs and tissues and has potential utility in disease diagnosis and treatment. However, the relationship between the annexin family and CHB remains unclear.
METHODS: Clinical samples from hepatitis patients and donors or healthy individuals were collected. Transcriptome sequencing in CHB liver tissues and HBV-infected cells were performed. HepG2.2.15 cells with the full-length HBV genome and HBV-infected HepG2-NTCP cell models were established. HBV-infected mouse model was constructed and adeno-associated virus was utilized.
RESULTS: ANXA4 expression was elevated during CHB infection. ANXA4 knockdown promoted HBV replication and aggravated liver injury, while ANXA4 overexpression alleviated that. Mechanistically, autophagy pathway was activated by ANXA4 deficiency, promoting autophagic degradation of minichromosome maintenance complex component 2 (MCM2). MCM2 inhibition activated HBV replication, while MCM2 overexpression attenuated ANXA4 deficiency-induced HBV replication and liver injury. Clinically, the expression of hepatitis B viral protein was negatively correlated with the ANXA4 levels, and CHB patients with high ANXA4 levels (> 8 ng/ml) showed higher sensitivity to interferon therapy.
CONCLUSIONS: ANXA4 functions as a protective factor during HBV infection. ANXA4 expression is elevated under HBV attack to restrict HBV replication by inhibiting autophagic degradation of MCM2, thereby alleviating liver injury and suppressing the CHB infection process. ANXA4 also enhances the sensitivity of CHB patients to interferon therapy. Therefore, ANXA4 is expected to be a new target for CHB treatment and prognostic evaluation.
Group 1 will receive daily basal insulin glargine with a scheduled bolus of meal insulin Novolog. Meal Novolog will be dosed at the time the subject starts to eat. If the premeal blood glucose (BG) is ≥ 150 mg/dL, additional Novolog will be administered based off the correctional scale at the same time as the prandial insulin. The dose of Novolog will be administered by the floor nurse as per usual standard of care.
BACKGROUND: Parkinson's disease (PD) patients with tremor-dominant (TD) and non-tremor-dominant (NTD) subtypes exhibit heterogeneity. Rapid identification of different motor subtypes may help to develop personalized treatment plans.
METHODS: The data were acquired from the Parkinson's Disease Progression Marker Initiative (PPMI). Following the identification of predictors utilizing recursive feature elimination (RFE), seven classical machine learning (ML) models, including logistic regression, support vector machine, decision tree, random forest, extreme gradient boosting, etc., were trained to predict patients' motor subtypes, evaluating the performance of models through the area under the receiver operating characteristic curve (AUC) and validating by the follow-up data.
RESULTS: The feature subset engendered by RFE encompassed 20 features, comprising some clinical assessments and cerebrospinal fluid α-synuclein (CSF α-syn). ML models fitted in the RFE subset performed better in the test and validation sets. The best performing model was support vector machines with the polynomial kernel (P-SVM), achieving an AUC of 0.898. Five-fold repeated cross-validation showed the P-SVM model with CSF α-syn performed better than the model without CSF α-syn (P = 0.034). The Shapley additive explanation plot (SHAP) illustrated that how the levels of each feature affect the predicted probability as NTD subtypes.
CONCLUSION: An interactive web application was developed based on the P-SVM model constructed from feature subset by RFE. It can identify the current motor subtypes of PD patients, making it easier to understand the status of patients and develop personalized treatment plans.
BACKGROUND: The vascular division sequence in video-assisted thoracic surgery (VATS) lung resection is usually determined by the handling difficulty due to the limited surgical view through the scope. However, upfront pulmonary vein division is theoretically desirable to avoid tumor cells spreading by surgical manipulation. Epithelial-mesenchymal transition (EMT) is associated with poor prognosis and an increased number of circulating tumor cells. The purpose of this study is to evaluate the effect of vascular division sequence and EMT on postoperative recurrence.
METHODS: We retrospectively investigated tissue microarrays of 282 lung adenocarcinomas surgically resected between 2001 and 2007. We excluded the cases with segmentectomy, wedge resection, dissemination, insufficient material for staining, or lack of medical records. The effect of vascular division sequence and clinicopathologic factors on recurrence was evaluated in 195 cases.
RESULTS: The upfront pulmonary vein division (V-first) was performed in 60 patients, and the upfront pulmonary artery division (A-first) was performed in 135 patients. The recurrence was observed in 67 patients (13 in V-first and 54 in A-first). Epithelial-mesenchymal transition activation was observed in 104 patients. Multivariable analysis with 195 patients revealed that lymph node metastasis and pleural invasion were risk factors for the recurrence. The stratified multivariable analysis showed that vascular division sequence (A-first) was a risk factor only in the EMT-negative group (91 patients). In the EMT-negative subset, the 5-year relapse-free survival rate was significantly lower in the A-first group than the V-first group (72.6% vs. 92.2%, p  =  0.0136).
CONCLUSIONS: The upfront pulmonary artery division might be a risk factor in patients without EMT activation.
Carefully consider the potential benefits and risks of meloxicam tablets and other treatment options before deciding to use meloxicam tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).

After observing the response to initial therapy with meloxicam tablets, the dose should be adjusted to suit an individual patient's needs.

For the relief of the signs and symptoms of osteoarthritis the recommended starting and maintenance oral dose of meloxicam is 7.5 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily. For the relief of the signs and symptoms of rheumatoid arthritis, the recommended starting and maintenance oral dose of meloxicam is 7.5 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily.

The maximum recommended daily oral dose of meloxicam is 15 mg regardless of formulation.

Meloxicam may be taken without regard to timing of meals.
Inhaled apomorphine, dry powder, VR040 at fine particle doses (FPD) of 0.2mg, 0.5mg and 0.8mg. A single dose, followed by a second dose at 12 minutes if efficacy end point was not attained.
BYOOVIZ (ranibizumab-nuna) is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab-nuna binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab-nuna, which lacks an Fc region, has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline. Tetracycline is not detectable in the final product.

BYOOVIZ (ranibizumab-nuna) injection is a sterile, clear to slightly opalescent and colorless to pale yellow solution in a single-dose glass vial for intravitreal use. BYOOVIZ is supplied as a preservative-free, sterile solution in a single-dose container designed to deliver 0.05 mL of 10 mg/mL BYOOVIZ (0.5 mg dose vial) aqueous solution with 10 mM histidine HCl, 10% α,α-trehalose dihydrate, 0.01% polysorbate 20, pH 5.5.
Healthcare professionals working as "ethical representatives" at the current ward (n=5) have recently gone through a basic ethics program. They have not being educated in "the one to five-step method and organized interprofessional sessions are not planned at the wards.